Company news

Fate Therapeutics, Inc. news in 2022

Fate Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemotherapy for Off-the-shelf, iPSC-derived Cell Therapies at 2022 ASH Annual Meeting

December 12, 2022

GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022

December 11, 2022

Fate Therapeutics Highlights iPSC-derived, Off-the-shelf CAR NK Cell Programs for Multiple Myeloma at 2022 ASH Annual Meeting

December 9, 2022

Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derived CAR T-cell Therapy at 2022 ASH Annual Meeting

December 9, 2022

Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors

November 6, 2022

Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the 2022 ASH Annual Meeting

November 2, 2022

Fate Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Operational Progress

November 2, 2022

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2022 Financial Results

October 23, 2022

Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the Society for Immunotherapy of Cancer 37th Annual Meeting

October 4, 2022

Fate Therapeutics to Participate at Upcoming September Investor Conferences

September 1, 2022

Fate Therapeutics Announces Preclinical Publication Highlighting Derivation of CD8αβ T Cells from TCR-CAR+ Induced Pluripotent Stem Cells

August 8, 2022

Fate Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Operational Progress

August 2, 2022

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2022 Financial Results

July 24, 2022

Fate Therapeutics Appoints Brian T. Powl as Chief Commercial Officer

June 29, 2022

Fate Therapeutics Announces Expansion of Solid Tumor Collaboration with ONO Pharmaceutical for Off-the-Shelf, iPSC-derived CAR NK and CAR T-Cell Cancer Immunotherapies

June 27, 2022

Fate Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference

June 2, 2022

Fate Therapeutics to Present at Upcoming May Investor Conferences

May 5, 2022

Fate Therapeutics Reports First Quarter 2022 Financial Results and Highlights Operational Progress

May 3, 2022

Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2022 Financial Results

April 21, 2022

Fate Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Operational Progress

February 27, 2022

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2021 Financial Results

February 15, 2022

Fate Therapeutics to Present at Upcoming February Investor Conferences

February 1, 2022

Fate Therapeutics Announces FDA Clearance for FT536, a First-in-class MICA/B-targeted CAR NK Cell Product Candidate for the Treatment of Solid Tumors

January 9, 2022

Calls in 2022

Decks in 2022